MX2020009929A - Compuestos organicos. - Google Patents
Compuestos organicos.Info
- Publication number
- MX2020009929A MX2020009929A MX2020009929A MX2020009929A MX2020009929A MX 2020009929 A MX2020009929 A MX 2020009929A MX 2020009929 A MX2020009929 A MX 2020009929A MX 2020009929 A MX2020009929 A MX 2020009929A MX 2020009929 A MX2020009929 A MX 2020009929A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- treatment
- organic compounds
- receptor
- carbolines
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 abstract 1
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862647482P | 2018-03-23 | 2018-03-23 | |
| PCT/US2019/023687 WO2019183546A1 (en) | 2018-03-23 | 2019-03-22 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009929A true MX2020009929A (es) | 2021-01-08 |
Family
ID=67987581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009929A MX2020009929A (es) | 2018-03-23 | 2019-03-22 | Compuestos organicos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210008065A1 (https=) |
| EP (1) | EP3768271B1 (https=) |
| JP (2) | JP2021519271A (https=) |
| CN (1) | CN112088004A (https=) |
| AU (2) | AU2019236860B2 (https=) |
| BR (1) | BR112020019181A2 (https=) |
| CA (1) | CA3095101A1 (https=) |
| DK (1) | DK3768271T3 (https=) |
| FI (1) | FI3768271T3 (https=) |
| IL (2) | IL303857B2 (https=) |
| MX (1) | MX2020009929A (https=) |
| WO (1) | WO2019183546A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL305990B2 (en) * | 2013-12-03 | 2025-12-01 | Intra Cellular Therapies Inc | Long-acting injectable composition comprising polymeric microspheres of heterocycle fused gamma-carboline compounds or a pharmaceutical composition for sustained or delayed release comprising the compounds and their use in the treatment of bipolar disorder i and/or bipolar ii disorder |
| CN108883111B (zh) | 2016-01-26 | 2021-10-08 | 细胞内治疗公司 | 有机化合物 |
| IL268970B2 (en) | 2017-03-24 | 2023-12-01 | Intra Cellular Therapies Inc | Oral transmucosal formulations of substituted heterocycle fused gamma carbolines |
| JP7224333B2 (ja) | 2017-07-26 | 2023-02-17 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| CN111107847A (zh) | 2017-09-26 | 2020-05-05 | 细胞内治疗公司 | 新的盐和晶体 |
| WO2019178484A1 (en) | 2018-03-16 | 2019-09-19 | Intra-Cellular Therapies, Inc. | Novel methods |
| AU2019240226B2 (en) | 2018-03-23 | 2024-11-28 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CA3106447A1 (en) | 2018-06-11 | 2019-12-19 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| CN112584837A (zh) | 2018-08-31 | 2021-03-30 | 细胞内治疗公司 | 新方法 |
| CA3108558A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
| IL283963B2 (en) | 2018-12-17 | 2025-01-01 | Intra Cellular Therapies Inc | Synthesis of condensed gamma-carbolines and converted heterocycles |
| WO2020132605A1 (en) | 2018-12-21 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP7673040B2 (ja) | 2019-07-07 | 2025-05-08 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規方法 |
| EP4034119A4 (en) | 2019-09-25 | 2023-10-18 | Intra-Cellular Therapies, Inc. | NOVEL METHODS |
| EP4072554A4 (en) | 2019-12-11 | 2023-12-20 | Intra-Cellular Therapies, Inc. | ORGANIC CONNECTION |
| JP7533361B2 (ja) * | 2021-05-26 | 2024-08-14 | 株式会社三洋物産 | 遊技機 |
| JP2025521115A (ja) | 2022-05-18 | 2025-07-08 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規方法 |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| EP4665344A1 (en) | 2023-02-17 | 2025-12-24 | Intra-Cellular Therapies, Inc. | Lumateperone and derivatives thereof for modulating the nervous system |
| WO2025111568A1 (en) | 2023-11-22 | 2025-05-30 | Intra-Cellular Therapies, Inc. | Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof |
| WO2025240804A1 (en) | 2024-05-16 | 2025-11-20 | Intra-Cellular Therapies, Inc. | Novel compositions, devices and methods |
| WO2025257090A1 (en) | 2024-06-10 | 2025-12-18 | Interquim, S.A. | Process for the preparation of synthesis intermediates of lumateperone and lumateperone analogues |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| CH656884A5 (de) | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
| US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| CN1074923C (zh) | 1993-11-19 | 2001-11-21 | 詹森药业有限公司 | 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类 |
| WO2000035419A2 (en) | 1998-12-17 | 2000-06-22 | Alza Corporation | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
| MXPA01012969A (es) | 1999-06-15 | 2003-10-14 | Bristol Myers Squibb Pharma Co | Gamma-carbolinas fusionadas de heterociclo sustituido. |
| US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
| US7071186B2 (en) | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
| US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| KR100699516B1 (ko) | 2002-07-29 | 2007-03-26 | 알자 코포레이션 | 팔리페리돈의 조절 전달을 위한 방법 및 복용 형태 |
| KR102065319B1 (ko) | 2007-03-12 | 2020-01-10 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
| JP5611846B2 (ja) | 2008-03-12 | 2014-10-22 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 置換ヘテロ環縮合ガンマ−カルボリン類固体 |
| CN105168219B (zh) | 2008-05-27 | 2018-11-20 | 细胞内治疗公司 | 用于睡眠障碍和其他疾病的方法和组合物 |
| EP2560676B8 (en) | 2010-04-22 | 2016-10-12 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2013155504A1 (en) | 2012-04-14 | 2013-10-17 | Intra-Cellular Therapies, Inc. | Novel methods |
| SG11201501894VA (en) * | 2012-09-14 | 2015-04-29 | Abbvie Inc | Tricyclic quinoline and quinoxaline derivatives |
| MX365969B (es) * | 2014-04-04 | 2019-06-21 | Intra Cellular Therapies Inc | Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio. |
| RU2016143091A (ru) * | 2014-04-04 | 2018-05-08 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| WO2017117514A1 (en) | 2015-12-31 | 2017-07-06 | Tung Roger D | Deuterated iti-007 |
| PL3407889T3 (pl) | 2016-03-25 | 2021-11-22 | Intra-Cellular Therapies, Inc. | Związki organiczne i ich zastosowanie w leczeniu lub zapobieganiu zaburzeniom ośrodkowego układu nerwowego |
-
2019
- 2019-03-22 WO PCT/US2019/023687 patent/WO2019183546A1/en not_active Ceased
- 2019-03-22 DK DK19771617.8T patent/DK3768271T3/da active
- 2019-03-22 AU AU2019236860A patent/AU2019236860B2/en active Active
- 2019-03-22 IL IL303857A patent/IL303857B2/en unknown
- 2019-03-22 FI FIEP19771617.8T patent/FI3768271T3/fi active
- 2019-03-22 BR BR112020019181-7A patent/BR112020019181A2/pt unknown
- 2019-03-22 EP EP19771617.8A patent/EP3768271B1/en active Active
- 2019-03-22 CA CA3095101A patent/CA3095101A1/en active Pending
- 2019-03-22 IL IL277509A patent/IL277509B2/en unknown
- 2019-03-22 US US17/040,893 patent/US20210008065A1/en active Pending
- 2019-03-22 CN CN201980028290.1A patent/CN112088004A/zh active Pending
- 2019-03-22 JP JP2020551349A patent/JP2021519271A/ja active Pending
- 2019-03-22 MX MX2020009929A patent/MX2020009929A/es unknown
-
2024
- 2024-06-26 JP JP2024102491A patent/JP2024123211A/ja active Pending
-
2025
- 2025-02-07 AU AU2025200857A patent/AU2025200857A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3768271A4 (en) | 2021-11-17 |
| IL303857B2 (en) | 2024-08-01 |
| IL277509A (en) | 2020-11-30 |
| EP3768271A1 (en) | 2021-01-27 |
| IL303857B1 (en) | 2024-04-01 |
| IL277509B2 (en) | 2023-11-01 |
| AU2025200857A1 (en) | 2025-02-27 |
| AU2019236860A1 (en) | 2020-10-22 |
| WO2019183546A1 (en) | 2019-09-26 |
| CN112088004A (zh) | 2020-12-15 |
| BR112020019181A2 (pt) | 2021-01-05 |
| IL303857A (en) | 2023-08-01 |
| DK3768271T3 (da) | 2026-03-02 |
| AU2019236860B2 (en) | 2024-11-14 |
| US20210008065A1 (en) | 2021-01-14 |
| FI3768271T3 (fi) | 2026-03-30 |
| EP3768271B1 (en) | 2026-02-18 |
| IL277509B1 (en) | 2023-07-01 |
| JP2024123211A (ja) | 2024-09-10 |
| CA3095101A1 (en) | 2019-09-26 |
| JP2021519271A (ja) | 2021-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020009929A (es) | Compuestos organicos. | |
| MX2020000967A (es) | Compuestos organicos. | |
| MX2021014508A (es) | Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio. | |
| MX2021013564A (es) | Gamma-carbolinas fusionadas con heterociclo deuterado. | |
| MX2018009158A (es) | Compuestos organicos. | |
| MX2016013046A (es) | Compuestos organicos. | |
| MX2021007217A (es) | Compuesto organico. | |
| MX2012012277A (es) | Compuestos organicos. | |
| MX2020009928A (es) | Compuestos organicos. | |
| MX2024011170A (es) | Compuestos organicos. | |
| MX2020000968A (es) | Compuestos organicos. | |
| IN2014DN08562A (https=) | ||
| ZA201800022B (en) | Substituted heterocyclyl derivatives as cdk inhibitors | |
| EA201891267A1 (ru) | Фармацевтическая композиция, содержащая действенный ингибитор urat1 | |
| WO2023178111A3 (en) | Organic compounds | |
| NI202100012A (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| MX380037B (es) | Antagonistas novedosos 5-ht2 | |
| ECSP20066271A (es) | Derivados de pirazo-tetrahidroisoquinolina como moduladores positivos del receptor de dopamina d1 | |
| MX381768B (es) | Combinación de antagonistas puros del receptor 5-ht6 con inhibidores de la acetilcolinesterasa. | |
| CL2019003467A1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| MX378799B (es) | Combinación de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda. | |
| PH12017501736B1 (en) | Indole derivatives | |
| EA202090397A1 (ru) | Фторопиперидиновые соединения в качестве чистых антагонистов 5-ht-рецептора |